Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > Pharmacy chains defend actions as landmark U.S. opioid trial nears its end
    Top Stories

    Pharmacy chains defend actions as landmark U.S. opioid trial nears its end

    Published by maria gbaf

    Posted on November 16, 2021

    3 min read

    Last updated: January 28, 2026

    An illustration depicting gender diversity in the fintech industry, highlighting women's contributions to finance leadership roles, aligning with the article's discussion on gender disparity in fintech.
    Gender diversity in fintech with a focus on women in leadership roles - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Pharmacy chains like CVS and Walgreens defend their actions as a landmark U.S. opioid trial nears its end, with potential nationwide implications.

    Pharmacy Chains Defend in Landmark U.S. Opioid Trial

    By Grant Segall

    CLEVELAND (Reuters) -Lawyers for pharmacy chains including CVS and Walgreens on Monday argued they were not to blame for the U.S. opioid epidemic, as jurors prepared to consider whether to hold them responsible for the devastation the drug crisis caused in two Ohio counties.

    Mark Lanier, a lawyer for Lake and Trumbull counties, told a federal jury in Cleveland that a verdict in the case against CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc would have ramifications across the country.

    The trial is the first the pharmacy chains have faced in thousands of lawsuits by states and local governments seeking to hold them liable for an epidemic that U.S. health officials say has led to nearly 500,000 opioid overdose deaths over two decades.

    “You get to decide what will be the most seminal case in pharmacy history,” Lanier said in his closing argument.

    He argued that companies created a public nuisance in the form of the epidemic by failing to prevent excessive amounts of addictive pain pills from flooding the counties or by stopping bogus prescriptions from being filled.

    “A pharmacy is not a gum ball machine,” Lanier said. “They have more responsibility than simply taking your money and getting you your pills.”

    Defense lawyers countered that the companies took steps to guard against the diversion of pills and blamed others for the deadly epidemic.

    “There are many, many actors who played a role in the opioid crisis: The manufacturers, government agencies, doctors, drug cartels,” CVS attorney Eric Delinsky said.

    Brian Swanson, a lawyer for Walgreens, said it had policies in place since 1997 to identify “red flags” of misuse and kept improving them.

    “A company that’s constantly updating and improving its policies is not a company acting intentionally to cause an opioid crisis,” he told jurors.

    LAWSUITS FILED NATIONWIDE

    Should the jurors find the pharmacies created a public nuisance, U.S. District Judge Dan Polster would decide how much they owe to abate, or address, it. The counties’ lawyers have said the costs are potentially $1 billion for each county.

    The Ohio trial follows recent setbacks for plaintiffs pursuing some of the 3,300 opioid cases filed against drug manufacturers, distributors and pharmacies.

    Oklahoma’s top court last Tuesday overturned a $465 million judgment https://www.reuters.com/business/oklahoma-court-overturns-465-million-opioid-award-against-johnson-johnson-2021-11-09 against drugmaker Johnson & Johnson, and a California judge this month ruled in favor of four drugmakers in a case brought by several large counties.

    Those lawsuits also accused the companies of creating a public nuisance. A similar lawsuit by Washington state against three drug distributors went to trial on Monday.

    (Reporting by Grant Segall in Cleveland and Nate Raymond in Boston; Editing by Will Dunham, Noeleen Walder, Aurora Ellis and Dan Grebler)

    Key Takeaways

    • •Pharmacy chains argue they are not to blame for opioid epidemic.
    • •Trial could set precedent for thousands of similar lawsuits.
    • •Defense claims pharmacies took steps to prevent misuse.
    • •Potential $1 billion cost per county if pharmacies are liable.
    • •Recent setbacks for plaintiffs in other opioid cases.

    Frequently Asked Questions about Pharmacy chains defend actions as landmark U.S. opioid trial nears its end

    1What is the main topic?

    The article discusses the defense of pharmacy chains in a landmark U.S. opioid trial and its potential implications.

    2Another relevant question?

    How might the trial's outcome affect future lawsuits? It could set a precedent for thousands of similar cases.

    3Third question about the topic?

    What are the potential financial implications? Pharmacies could face costs of $1 billion per county if found liable.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostThe Morning After COP26 – The Broader Regulatory Outlook in 2022
    Next Top Stories PostAstraZeneca-Oxford COVID-19 vaccine supply hits two billion doses